Logo image of ASMB

ASSEMBLY BIOSCIENCES INC (ASMB) Stock Fundamental Analysis

USA - NASDAQ:ASMB - US0453962070 - Common Stock

24.73 USD
+0.06 (+0.24%)
Last: 9/29/2025, 3:22:59 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ASMB. ASMB was compared to 536 industry peers in the Biotechnology industry. ASMB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, ASMB is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ASMB has reported negative net income.
In the past year ASMB has reported a negative cash flow from operations.
ASMB had negative earnings in each of the past 5 years.
ASMB had negative operating cash flow in 4 of the past 5 years.
ASMB Yearly Net Income VS EBIT VS OCF VS FCFASMB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

ASMB has a Return On Assets of -48.23%. This is comparable to the rest of the industry: ASMB outperforms 51.68% of its industry peers.
With a Return On Equity value of -215.27%, ASMB is not doing good in the industry: 68.28% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -48.23%
ROE -215.27%
ROIC N/A
ROA(3y)-56.64%
ROA(5y)-51.96%
ROE(3y)-127.35%
ROE(5y)-96.95%
ROIC(3y)N/A
ROIC(5y)N/A
ASMB Yearly ROA, ROE, ROICASMB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

ASMB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ASMB Yearly Profit, Operating, Gross MarginsASMB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

5

2. Health

2.1 Basic Checks

ASMB does not have a ROIC to compare to the WACC, probably because it is not profitable.
ASMB has more shares outstanding than it did 1 year ago.
ASMB has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ASMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ASMB Yearly Shares OutstandingASMB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
ASMB Yearly Total Debt VS Total AssetsASMB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -12.43, we must say that ASMB is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ASMB (-12.43) is worse than 77.61% of its industry peers.
There is no outstanding debt for ASMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.43
ROIC/WACCN/A
WACC10.06%
ASMB Yearly LT Debt VS Equity VS FCFASMB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 1.64 indicates that ASMB should not have too much problems paying its short term obligations.
ASMB's Current ratio of 1.64 is on the low side compared to the rest of the industry. ASMB is outperformed by 79.85% of its industry peers.
ASMB has a Quick Ratio of 1.64. This is a normal value and indicates that ASMB is financially healthy and should not expect problems in meeting its short term obligations.
ASMB has a worse Quick ratio (1.64) than 79.29% of its industry peers.
Industry RankSector Rank
Current Ratio 1.64
Quick Ratio 1.64
ASMB Yearly Current Assets VS Current LiabilitesASMB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 38.21% over the past year.
Looking at the last year, ASMB shows a very strong growth in Revenue. The Revenue has grown by 54.77%.
The Revenue has been growing by 12.31% on average over the past years. This is quite good.
EPS 1Y (TTM)38.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.83%
Revenue 1Y (TTM)54.77%
Revenue growth 3Y65.83%
Revenue growth 5Y12.31%
Sales Q2Q%12.81%

3.2 Future

The Earnings Per Share is expected to grow by 13.53% on average over the next years. This is quite good.
ASMB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.24% yearly.
EPS Next Y42.09%
EPS Next 2Y27.36%
EPS Next 3Y33.1%
EPS Next 5Y13.53%
Revenue Next Year16.24%
Revenue Next 2Y-12.89%
Revenue Next 3Y46.05%
Revenue Next 5Y19.24%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ASMB Yearly Revenue VS EstimatesASMB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
ASMB Yearly EPS VS EstimatesASMB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30 -40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ASMB. In the last year negative earnings were reported.
Also next year ASMB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASMB Price Earnings VS Forward Price EarningsASMB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ASMB Per share dataASMB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

ASMB's earnings are expected to grow with 33.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.36%
EPS Next 3Y33.1%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ASMB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASSEMBLY BIOSCIENCES INC

NASDAQ:ASMB (9/29/2025, 3:22:59 PM)

24.73

+0.06 (+0.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-05 2025-11-05
Inst Owners23.27%
Inst Owner Change-0.05%
Ins Owners4.52%
Ins Owner Change0.01%
Market Cap327.92M
Analysts86
Price Target39.02 (57.78%)
Short Float %11.18%
Short Ratio8.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.39%
Min EPS beat(2)4.47%
Max EPS beat(2)28.31%
EPS beat(4)4
Avg EPS beat(4)21.01%
Min EPS beat(4)4.47%
Max EPS beat(4)28.31%
EPS beat(8)7
Avg EPS beat(8)19.79%
EPS beat(12)7
Avg EPS beat(12)12.3%
EPS beat(16)10
Avg EPS beat(16)11.95%
Revenue beat(2)2
Avg Revenue beat(2)37.63%
Min Revenue beat(2)24.54%
Max Revenue beat(2)50.71%
Revenue beat(4)3
Avg Revenue beat(4)23.01%
Min Revenue beat(4)-22.37%
Max Revenue beat(4)50.71%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.52%
PT rev (3m)20.79%
EPS NQ rev (1m)20%
EPS NQ rev (3m)46.67%
EPS NY rev (1m)21.77%
EPS NY rev (3m)22.46%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)14.24%
Revenue NY rev (1m)-0.77%
Revenue NY rev (3m)11.53%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.86
P/FCF N/A
P/OCF N/A
P/B 18.12
P/tB 18.12
EV/EBITDA N/A
EPS(TTM)-5.58
EYN/A
EPS(NY)-2.54
Fwd EYN/A
FCF(TTM)-4.21
FCFYN/A
OCF(TTM)-4.21
OCFYN/A
SpS2.51
BVpS1.37
TBVpS1.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -48.23%
ROE -215.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.64%
ROA(5y)-51.96%
ROE(3y)-127.35%
ROE(5y)-96.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.64
Quick Ratio 1.64
Altman-Z -12.43
F-Score3
WACC10.06%
ROIC/WACCN/A
Cap/Depr(3y)32.95%
Cap/Depr(5y)216.9%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.83%
EPS Next Y42.09%
EPS Next 2Y27.36%
EPS Next 3Y33.1%
EPS Next 5Y13.53%
Revenue 1Y (TTM)54.77%
Revenue growth 3Y65.83%
Revenue growth 5Y12.31%
Sales Q2Q%12.81%
Revenue Next Year16.24%
Revenue Next 2Y-12.89%
Revenue Next 3Y46.05%
Revenue Next 5Y19.24%
EBIT growth 1Y13.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year11.88%
EBIT Next 3Y39.36%
EBIT Next 5Y28.3%
FCF growth 1Y26.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.64%
OCF growth 3YN/A
OCF growth 5YN/A